臨床婦人科産科68巻12号

2014年12月発行

今月の臨床 子宮内膜症治療の未来図 発症機序からみた予防・治療戦略

3．エピジェネティクス異常からみた子宮内膜症の治療戦略

著者： 奈須家栄¹² 甲斐健太郎¹ 楢原久司¹

所属機関： ¹大分大学医学部産科婦人科 ²大分大学医学部地域医療支援システム・産婦人科分野

ページ範囲：P.1164 - P.1169

●子宮内膜症に特徴的な形質の獲得にはエピジェネティクス異常が関与しており，病因として注目されている．

●マイクロアレイを用いた網羅的解析法により，子宮内膜症におけるエピジェネティクス異常が徐々に解明されている．

●子宮内膜症の治療薬として，エピジェネティクス異常の修正を目的とする薬物の開発が期待されている．

参考文献

1） Giudice LC, et al : Endometriosis. Lancet 364 : 1789─1799, 2004

2） Practice Committee of the American Society for Reproductive Medicine : Endometriosis and infertility. Fertil Steril 81 : 1441─1446, 2004

3） Farquhar CM : Extracts from the “clinical evidence”. Endometriosis. BMJ 32 : 1449─1452, 2000

4） Kokura K, et al : The Ski protein family is required for MeCP2-mediated transcriptional repression. J Biol Chem 276 : 34115─34121, 2001

5） Jones PA, et al : The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 : 415─428, 2002

6） Ehrlich M : Expression of various genes is controlled by DNA methylation during mammalian development. J Cell Biochem 88 : 899─910, 2003

7） Bogdanovic O, et al : DNA methylation and methyl-CpG binding proteins : developmental requirements and function. Chromosoma 118 : 549─565, 2009

8） Reik W, et al : Epigenetic reprogramming in mammalian development. Science 293 : 1089─1093, 2001

9） Robertson KD, et al : DNA methylation in health and disease. Nat Rev Genet 1 : 11─19, 2000

10） Ting AH, et al : Mammalian DNA methyltransferase 1 : inspiration for new directions. Cell Cycle 3 : 1024─1026, 2004

11） Hendrich B, et al : The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet 19 : 269─277, 2003

12） Wu Y, et al : Promoter hypermethylation of progesterone receptor isoform B（PR-B）in endometriosis. Epigenetics 1 : 106─111, 2006

13） Wu Y, et al : Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci 14 : 374─382, 2007

14） Wu Y, et al : Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol 193 : 371─380, 2005

15） Xue Q, et al : Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod 77 : 681─687, 2007

16） Xue Q, et al : Transcriptional Activation of steroidogenic factor-1 by hypomethylation of the 5’ CpG island in endometriosis. J Clin Endocrinol Metab 92 : 3261─3267, 2007

17） Izawa M, et al : An epigenetic disorder may cause aberrant expression of aromatase gene in endometriotic stromal cells. Fertil Steril 89 : 1390─1396, 2008

18） Izawa M, et al : Demethylation of a nonpromoter cytosine-phosphate-guanine island in the aromatase gene may cause the aberrant up-regulation in endometriotic tissues. Fertil Steril 95 : 33─39, 2011

19） Abe W, et al : miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells. Hum Reprod 28 : 750─761, 2013

20） Robertson KD : DNA methylation and human disease. Nat Rev Genet 6 : 597─610, 2005

21） Wu Y, et al : Aberrant expression of deoxyribonucleic acid methyltransferases DNMT1, DNMT3A, and DNMT3B in women with endometriosis. Fertil Steril 87 : 24─32, 2007

22） Yoo CB, et al : Epigenetic therapy of cancer : past, present and future. Nat Rev Drug Discov 5 : 37─50, 2006

23） Egger G, et al : Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 : 457─463, 2004

24） Brena RM, et al : Quantitative assessment of DNA methylation : potential applications for disease diagnosis, classification, and prognosis in clinical settings, J Mol Med 84 : 365─377, 2006

25） Esteller M : Epigenetics in cancer. N Engl J Med 358 : 1148─1159, 2008

26） Foubister V : Drug reactivates genes to inhibit cancer. Drug Discov Today 8 : 430─431, 2003

27） Scott GK, et al : Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66 : 1277─1281, 2006

28） Lin X, et al : Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase（GSTP1）expression in human prostate cancer cells by treatment with procainamide. Cancer Res 61 : 8611─8616, 2001

29） Noguchi M, et al : Inhibitory effect of the tea polyphenol，（−）-epigallocatechin gallate, on growth of cervical adenocarcinoma cell lines. Cancer Lett 234 : 135─142, 2006

30） Davis AJ, et al : Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 21 : 85─97, 2003

31） Korkmaz A, et al : Epigenetic regulation : a new research area for melatonin? J Pineal Res 44 : 41─44, 2007

32） Flynn J, et al : A potent cell-active allosteric inhibitor of murine DNA cytosine C5 methyltransferase. J Biol Chem 278 : 8238─8243, 2003

33） Mai A, et al : Histone deacetylation in epigenetics : an attractive target for anticancer therapy. Med Res Rev 25 : 261─309, 2005

34） Kawano Y, et al : Application of the histone deacetylase inhibitors for the treatment of endometriosis : histone modifications as pathogenesis and novel therapeutic target. Hum Reprod 26 : 2486─2498, 2011

35） Imesch P, et al : Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells. Fertil Steril 100 : 770─776, 2013

36） Monteiro JB, et al : Endometriosis is characterized by a distinct pattern of histone 3 and histone 4 lysine modifications. Reprod Sci 21 : 305─318, 2014

37） Imesch P, et al : Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertil Steril 94 : 2838─2842, 2010

38） Kawano Y, et al : CCAAT/enhancer-binding protein α is epigenetically silenced by histone deacetylation in endometriosis and promotes the pathogenesis of endometriosis. J Clin Endocrinol Metab 98 : E1474─E1482, 2013

39） Kai K, et al : Death Receptor 6 is Epigenetically Silenced by Histone Deacetylation in Endometriosis and Promotes the Pathogenesis of Endometriosis. Am J Reprod Immunol 70 : 485─496, 2013

40） Wu Y, et al : Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 137 : 198─203, 2008

41） Wu Y, et al : Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 137 : 198─203, 2008

42） Wu Y, et al : Prolonged stimulation with tumor necrosis factor-α induced partial methylation at PR-B promoter in immortalized epithelial-like endometriotic cells. Fertil Steril 90 : 234─237, 2008

43） Wu Y, et al : Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. Fertil Steril 91（Suppl） : 2142─2147, 2009

44） Lu Y, et al : Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum Reprod 25 : 1014─1025, 2010

45） Liu M, et al : Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats. Reprod Sci 19 : 360─373, 2012

46） Liu X, et al : A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril 89 : 246─250, 2008